Abstract
Introduction: Parallel with the emerging results of the FAST-Forward (FF) trial, we implemented ultrahypofractionated radiation therapy (RT) for early-stage breast cancer in our clinic at the beginning of the COVID-19 pandemic [Brunt 2020]. This scheme of 26 Gy in 5 consecutive fractions, was given to all breast cancer patients referred for postoperative RT of the breast only. Uniquely, in view of the pandemic, we also gave a single ultrahypofractionated sequential tumourbed boost of 6 Gy, if indicated according to our local protocol.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
